Form 4: Thermo Fisher Director Acquires Phantom Stock Units

Thermo Fisher Scientific Director Karen S. Lynch acquired 67.31 phantom stock units through the company's deferred compensation plan.

Summary

• Karen S. Lynch, a Director at Thermo Fisher Scientific Inc. (TMO), acquired 67.31 phantom stock units.
• The transaction occurred on September 27, 2025, as part of the Issuer's Deferred Compensation Plan for Directors.
• Each phantom stock unit was credited at a price of $464.24.
• Phantom stock units are convertible into Common Stock on a 1-for-1 basis.
• Following this transaction, Karen S. Lynch beneficially owns 171.54 derivative securities (phantom stock units).
• Directors' retainers are deferred quarterly under the plan as Common Stock units based on the closing price of the stock at quarter end.
• The shares are distributable as stock upon cessation of director service (for any reason) or a change of control.

Sentiment

Score: 7

Explanation: The transaction is a positive signal as it increases director alignment with shareholders through equity ownership, even though it's part of a compensation plan rather than an open-market purchase. It reflects routine, expected corporate governance.

Positives

• The acquisition of phantom stock units increases the director's beneficial ownership, aligning their interests more closely with shareholders.
• Participation in the deferred compensation plan demonstrates the director's commitment to the company's long-term performance.

Negatives

• This transaction is part of a compensation plan, not an open-market purchase, which typically signals a more direct investment decision.

Future Outlook

The acquired phantom stock units will be distributable as common stock upon the cessation of director service for any reason or in the event of a change of control.

Management Comments

• Directors' retainers are deferred quarterly under the Plan as Common Stock units based on the closing price of the stock as of the quarter end.

Industry Context

This type of transaction, involving deferred compensation in the form of equity units for directors, is a common practice across publicly traded companies, particularly in the life sciences and technology sectors, to align director incentives with shareholder value.

Comparison to Industry Standards

• Deferred compensation plans for directors, often involving equity-based awards like phantom stock units, are standard practice in corporate governance across industries, including healthcare and scientific instruments. Companies like Danaher Corporation and Agilent Technologies also utilize similar mechanisms to compensate and align their board members.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value through equity ownership.
• Management: Reinforces the existing compensation structure for directors.

Next Steps

• The phantom stock units will be converted into common stock and distributed upon the reporting person's cessation of director service or a change of control at Thermo Fisher Scientific.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled acquisition of phantom stock units by a director as part of a deferred compensation plan. While it signifies continued alignment of interests between the director and shareholders, it does not represent a new, discretionary investment decision that would typically warrant a 'buy' or 'sell' recommendation. It's a standard governance event, reinforcing a 'hold' stance for existing investors.

Keywords

Thermo Fisher Scientific, TMO, Insider Transaction, Form 4, Phantom Stock Units, Deferred Compensation, Director Compensation, Equity Compensation